HHS Overrules FDA Scientists on Six Peptides, Easing Access Despite Safety Concerns

In a move that has sparked debate among medical professionals, the U.S. Department of Health and Human Services (HHS) has greenlit six peptides for easier access, despite opposition from FDA scientists who expressed concerns over their safety and efficacy. This policy shift, announced in 2023, aims to provide American citizens with simpler access to unverified peptide medications, a change that is particularly significant in the wellness industry where these compounds are widely used.

According to reports, the policy was championed by U.S. Health Secretary Robert F Kennedy Jr., who has spoken favorably about the use of these peptide drugs. Kennedy even shared his personal experience with one such peptide, BPC-157, which he used to treat a muscle injury. However, the decision to ease access to these peptides comes at a time when the FDA has listed several peptides as substances not suitable for compounding due to potential risks, highlighting the tension between the desire for wider access and the need for safety assurance.

The policy, which directs the FDA not to act against pharmacies selling specific peptides, includes safety measures suggested by FDA staff. These measures include requirements for peptide ingredients to come from FDA-registered factories, aiming to mitigate some of the risks associated with these unproven medications. Despite these precautions, the FDA has continued to warn Americans about the safety risks linked to unproven peptides, emphasizing the importance of thorough vetting before widespread use.

Traditionally, decisions regarding compounding have been made by the FDA, not the HHS. This latest policy marks a departure from that norm, with the HHS taking a more active role in shaping access to these medications. The issue of compounding safety gained prominence following a 2012 fungal meningitis outbreak, underscoring the critical nature of ensuring that compounded medications meet high standards of safety and effectiveness.

While the policy has received support from the HHS and some users of peptides, it has faced criticism from FDA scientists who were largely excluded from the creation of this policy. Their concerns highlight the ongoing debate about the balance between accessibility and safety in the realm of peptide medications. As the policy takes effect, it will be closely watched to see how it impacts both the wellness industry and public health.

What we know

• - FDA scientists opposed the decision to make peptide access easier. ¹²³
• - Peptides covered by the policy have not been approved as safe and effective by the FDA. ²³
• - In 2023, the FDA listed several peptides as unsuitable for compounding due to potential risks. ²³
• - The policy aims to allow simpler access to unverified peptide medications. ¹
• - Robert F Kennedy Jr. supports the use of these peptide drugs. ¹²
• - The policy covers a few injectable peptides used in the wellness industry. ²
• - The policy directs the FDA not to act against pharmacies selling specific peptides. ²
• - The policy includes safety measures suggested by FDA staff. ²³
• - The FDA warns Americans about safety risks associated with unproven peptides. ²
• - Most FDA scientific staff had minimal involvement in creating this policy. ¹
• - Kennedy described using BPC-157 to treat a muscle injury. ²
• - Decisions about compounding have traditionally been made by the FDA, not HHS. ²
• - The issue of compounding safety gained prominence after a 2012 fungal meningitis outbreak. ²
• - Many users obtain peptides directly from online sellers rather than through doctors or pharmacies. ²